UPC

Universe Pharmaceuticals Inc. (UPC) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

UPC’s negative TTM ROIC and ROCE indicate it is not converting any proprietary asset base into excess returns, which is inconsistent with durable intangible-driven pricing power versus peers.

The absence of provided evidence for brand premium, patents, or regulated exclusivity means any intangible advantage appears limited relative to peers with clearer IP or franchise protection.

No 5-year margin or return history was provided, so there is no support for a persistent intangible moat that has held up through a full cycle versus competitors.

Switching Costs

Score:

A TTM cash conversion cycle of 428 days suggests working-capital intensity rather than customer lock-in, which usually points to low switching friction versus peers with recurring or embedded usage.

Negative ROIC implies customers are not being retained at economics strong enough to create durable renewal leverage, which weakens evidence of meaningful switching costs.

No filing-based evidence was provided for contracts, integration depth, or mission-critical workflows, so switching costs cannot be shown to exceed peer norms.

Network Effects

Score:

The available metrics do not show user growth, ecosystem participation, or transaction density that would indicate self-reinforcing network effects versus peers.

Negative returns on capital suggest the business is not yet monetizing any scale-driven flywheel in a way that compounds with usage, which is inconsistent with a strong network moat.

No Tier 1 evidence was provided for platform dependency, multi-sided adoption, or data advantages, so network effects appear absent or immaterial.

Cost Advantage

Score:

Asset turnover of 0.25x indicates low asset productivity, which argues against a structural cost advantage versus peers that can generate more revenue per dollar of assets.

Negative ROIC and ROCE imply the cost structure is not translating into superior unit economics, so pricing flexibility is likely limited relative to stronger operators.

No evidence was provided for scale purchasing, logistics density, or process superiority, so any cost advantage appears weak and not durable.

Efficient Scale

Score:

The provided data do not show UPC operating in a niche where one or two firms can serve the market efficiently, so efficient-scale protection versus peers is not established.

Negative capital returns suggest competition is still absorbing economic rents rather than a stable oligopoly preserving margins through limited capacity.

No filing evidence was provided for regulated barriers, exclusive infrastructure, or natural-monopoly characteristics, so efficient scale looks weak.

Overall Score

Score:

UPC shows no clear evidence of a durable economic moat versus peers, as negative TTM ROIC/ROCE, very low asset turnover, and an extremely long cash conversion cycle point to weak pricing power and limited structural advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Universe Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →